These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36990839)

  • 1. Stereotactic body radiotherapy in pancreatic adenocarcinoma.
    de la Pinta C
    Hepatobiliary Pancreat Dis Int; 2024 Feb; 23(1):14-19. PubMed ID: 36990839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.
    Paiella S; Malleo G; Simoni N; Micera R; Guariglia S; Cavedon C; Marchegiani G; Esposito A; Landoni L; Casetti L; Tuveri M; Milella M; Secchettin E; Manzini G; Bovo C; De Pastena M; Fontana M; Salvia R; Mazzarotto R; Bassi C
    BMC Cancer; 2021 Feb; 21(1):165. PubMed ID: 33593311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
    Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
    Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
    Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
    Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.
    Jiang W; Haque W; Verma V; Butler EB; Teh BS
    Acta Oncol; 2019 Sep; 58(9):1259-1266. PubMed ID: 31237185
    [No Abstract]   [Full Text] [Related]  

  • 6. Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design.
    Hoffe SE; Aguilera TA; Parikh PJ; Ghaly MM; Herman JM; Caster JM; Kim DW; Costello J; Malafa MP; Moser EC; Kennedy EP; Terry K; Kurman M
    Future Oncol; 2024 Mar; 20(8):437-446. PubMed ID: 38264869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review.
    de Geus SWL; Eskander MF; Kasumova GG; Ng SC; Kent TS; Mancias JD; Callery MP; Mahadevan A; Tseng JF
    Cancer; 2017 Nov; 123(21):4158-4167. PubMed ID: 28708929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma.
    Gurka MK; Kim C; He AR; Charabaty A; Haddad N; Turocy J; Johnson L; Jackson P; Weiner LM; Marshall JL; Collins SP; Pishvaian MJ; Unger K
    Am J Clin Oncol; 2017 Apr; 40(2):152-157. PubMed ID: 25171298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of stereotactic body radiotherapy in advanced pancreatic cancers in Australia.
    Kim L; Nguyen N; Singhal N; Phan VA; Iankov I; Le H
    J Med Radiat Sci; 2019 Mar; 66(1):54-61. PubMed ID: 30411540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
    Bouchart C; Navez J; Borbath I; Geboes K; Vandamme T; Closset J; Moretti L; Demetter P; Paesmans M; Van Laethem JL
    BMC Cancer; 2023 Sep; 23(1):891. PubMed ID: 37735634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1).
    Arcelli A; Buwenge M; Macchia G; Bertini F; Guido A; Deodato F; Cilla S; Scotti V; Rosetto ME; Djan I; Parisi S; Mattiucci GC; Cellini F; Fiore M; Bonomo P; Belgioia L; Niespolo RM; Gabriele P; Di Marco M; Simoni N; Mazzarotto R; Morganti AG;
    Cancer Med; 2020 Nov; 9(21):7879-7887. PubMed ID: 32910549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).
    Pavic M; Niyazi M; Wilke L; Corradini S; Vornhülz M; Mansmann U; Al Tawil A; Fritsch R; Hörner-Rieber J; Debus J; Guckenberger M; Belka C; Mayerle J; Beyer G
    Radiat Oncol; 2022 Jan; 17(1):18. PubMed ID: 35078490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
    Park JJ; Hajj C; Reyngold M; Shi W; Zhang Z; Cuaron JJ; Crane CH; O'Reilly EM; Lowery MA; Yu KH; Goodman KA; Wu AJ
    Acta Oncol; 2017 Dec; 56(12):1746-1753. PubMed ID: 28661823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
    Wild AT; Herman JM; Dholakia AS; Moningi S; Lu Y; Rosati LM; Hacker-Prietz A; Assadi RK; Saeed AM; Pawlik TM; Jaffee EM; Laheru DA; Tran PT; Weiss MJ; Wolfgang CL; Ford E; Grossman SA; Ye X; Ellsworth SG
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):571-9. PubMed ID: 26867885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma.
    Simoni N; Micera R; Paiella S; Guariglia S; Zivelonghi E; Malleo G; Rossi G; Addari L; Giuliani T; Pollini T; Cavedon C; Salvia R; Milella M; Bassi C; Mazzarotto R
    Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):e31-e38. PubMed ID: 32682686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Body Radiotherapy - Current Indications.
    Burkoň P; Slavik M; Kazda T; Pospíšil P; Prochazka T; Vrzal M; Šlampa P
    Klin Onkol; 2019; 32(1):10-24. PubMed ID: 30894002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.
    Panje C; Andratschke N; Brunner TB; Niyazi M; Guckenberger M
    Strahlenther Onkol; 2016 Dec; 192(12):875-885. PubMed ID: 27778052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma.
    Chapman BC; Gleisner A; Rigg D; Meguid C; Goodman K; Brauer B; Gajdos C; Schulick RD; Edil BH; McCarter MD
    J Surg Oncol; 2018 Apr; 117(5):1073-1083. PubMed ID: 29448308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
    Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
    Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
    Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL
    Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.